BofA raised the firm’s price target on Incyte (INCY) to $89 from $87 and keeps a Buy rating on the shares. After Incyte reported Q1 results, the firm cites mainly higher cash estimates for its revised price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte Reports Strong Q1 2025 Financial Growth
- Incyte’s Q1 2025 Earnings: Strong Growth and Optimism
- Incyte’s Promising Growth Potential and Strategic Positioning Amidst Market Challenges
- Morning Movers: Hims & Hers skyrockets following obesity pact with Novo Nordisk
- Incyte’s Mixed Performance and Future Uncertainties Justify Hold Rating